Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

PI3K kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PI3K (64) Akt (3) Amino Acid Derivatives (1) Antibiotic (2) Apoptosis (13) ATM/ATR (5) Autophagy (6) Casein Kinase (6) CDK (3) Cytochrome P450 (1) DNA-PK (3) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) G Protein-coupled Receptor Kinase (GRK) (1) IKK (1) Integrin (1) Ligands for Target Protein for PROTAC (1) Lipase (1) mTOR (18) NF-κB (1) Organoid (2) PI4K (1) PKC (1) Polo-like Kinase (PLK) (3) PROTACs (1) RET (1) ROR (1) SphK (1)
By Research Areas:	Cancer (67) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (9) Metabolic Disease (2)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: PI3K

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143275

HL-8	PI3K	Cancer
HL-8 is a PROTAC molecule targeting PI3K kinase. HL-8 has a significant and complete degradation effect on PI3K kinase at a concentration of 10 μM within 8 h. HL-8 has the potential for the research of cancer diseases .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-10620

PI3K-IN-22	PI3K mTOR	Cancer
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC₅₀s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR* inhibitor with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-142677

PI3K-IN-27	PI3K	Inflammation/Immunology Cancer
PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .

HY-139880

PI3Kγ inhibitor 5	PI3K	Cancer
PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ *(PI3Kγ)* with an IC₅₀ value of 34 nM.

HY-155975

PI3Kδ-IN-14	PI3K	Inflammation/Immunology
PI3Kδ-IN-14 (Compound (S)-29) is a selective PI3Kδ inhibitor (IC₅₀: 0.8 nM, K_d: 84.8 nM). PI3Kδ-IN-14 binds to the ATP-binding site of the kinase domain of PI3Kδ. PI3Kδ-IN-14 has anti-inflammatory activity by inhibiting the PI3K/AKT pathway. PI3Kδ-IN-14 ameliorates acute lung injury (ALI) .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-141690A

PI3K-IN-19 hydrochloride	PI3K	Cancer
PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2017153220, step 5 .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-160283

PI3K-IN-50	PI3K	Cancer
PI3K-IN-50 is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2023239710A1, example 35 .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

HY-158688

PI3Kδ-IN-21	PI3K	Inflammation/Immunology
PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC₅₀ of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model .

HY-101115

PI3K-IN-6	PI3K	Cancer
PI3K-IN-6 (compound 20a) is an oral active and highly selective *phosphoinositide 3-kinase* (PI3K) β/δ inhibitor, with IC₅₀** values of 7.8 nM/5.3 nM for PI3K β/δ, respectively. PI3K-IN-6 (compound 20a) has potential top treat phosphatase and tensin homolog (PTEN) feficient tumors .

HY-15346

Copanlisib 20+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 20+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-13246

Apitolisib 10+ Cited Publications GDC-0980; GNE 390; RG 7422	PI3K mTOR Apoptosis	Cancer
Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I *PI3* kinase and mTOR kinase (TORC1/2) inhibitor with IC₅₀s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a K_i of 17 nM for mTOR.

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-106006

RV-1729	PI3K	Others Inflammation/Immunology
RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ). RV-1729 identifies inhibition of the PI3K isotype by quantifying the release of phosphatidylinositol 3,4, 5-triphosphate (PIP3) (IC₅₀=12 nM), showing twice the selectivity for PI3Kδ relative to PI3Kγ. RV-1729 is also 16 times more selective to PI3Kα. RV-1729 regulates immune and inflammatory responses by inhibiting PI3Kδ. RV-1729 can be used in studies of asthma and chronic obstructive pulmonary disease (COPD) .

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective PI3Kα inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-136765

PI3K-IN-11	PI3K	Cancer
PI3K-IN-11 (compound 13) is a *PI3K* inhibitor, which selectively inhibits PI3Kα, PI3Kβ, PI3K, and PI3Kδ (IC₅₀s=6.4, 13, 8, and 11 nM, respectively) over mTOR (IC₅₀=2.9 μM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 μg/mL. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.

HY-10108

LY294002 Maximum Cited Publications 792 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of *PI3K* with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC₅₀ of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4?μM. LY294002 is an apoptosis activator .

HY-15346R

Copanlisib (Standard)	PI3K Apoptosis	Cancer
Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-11002

CP-466722 5 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of ATM, with an IC₅₀ of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-116191

WJD008	PI3K mTOR	Cancer
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and mTOR and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .

HY-12948

AMG319	PI3K	Cancer
AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC₅₀ of 18 nM.

HY-15174

Dactolisib Tosylate 55+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual *PI3K* and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-131910

IHMT-PI3Kδ-372	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-156406

PITCOIN4	PI3K	Inflammation/Immunology
PITCOIN4 is a highly selective Class II Alpha *PI3K-C2α* inhibitor. PITCOIN4 shows nanomolar inhibition of PI3K-C2α and >100-fold selectivity in a general kinase panel .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-143277

HL-2	Ligands for Target Protein for PROTAC	Cancer
HL-2 is a ligand of the target protein PI3K kinase of HL-8 (HY-143275), which can be used for PROTAC synthesis .

HY-161366

OMS14	PI3K	Cancer
OMS14 is exhibits inhibitory activity for phosphoinositide 3-kinase γ (PI3Kγ) and PIK3CD/PIK3R1, which inhibits 19% PI3Kγ and 65% PIK3CD/PIK3R1 activity at 100 μM. OMS14 exhibits anticancer efficacy in various cancer cells .

HY-100716

Eganelisib 15+ Cited Publications IPI-549	PI3K	Cancer
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC₅₀ of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases .

HY-100603A

(S)-GSK-F1	PI3K PI4K	Infection
(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC₅₀ of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model .

HY-135526

Demethoxyviridiol Desmethoxyviridiol	PI3K	Infection
Demethoxyviridiol is a mycotoxin originally isolated from N. hinnuleum. Demethoxyviridiol induces lethality in day-old cockerels (LD₅₀=4.2 mg/kg). Demethoxyviridiol is also an inhibitor of phosphatidylinositol 3-kinase (PI3K).

HY-135827A

Roginolisib hemifumarate MSC2360844 hemifumarate; IOA-244 hemifumarate	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC₅₀ of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases .

HY-135827

Roginolisib MSC2360844; IOA-244	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC₅₀ of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases .

HY-117923

PF-06465603	mTOR PI3K	Cancer
PF-06465603 is a highly potent and selective ATP-competitive kinase inhibitor and a class 1 PI3K and mTOR inhibitor. PF-06465603 is a metabolite of PF-04691502 with a terminal carboxylic acid structure .

HY-114457

Phosphatidylinositol 4,5-bisphosphate L-alpha-Phosphatidylinositol-4,5-bisphosphate	PI3K	Others
Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate), a phospholipid component of cell membranes, is a substrate for phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) and as a primary messenger .

HY-108606

PI-828 1 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual *PI3K* and *casein kinase* 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2** in lipid kinase assay, respectively .

HY-109198

Zandelisib ME-401; PWT-143	PI3K	Cancer
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC₅₀ of 3.5 nM. Zandelisib functions as an antineoplastic .

HY-144686

ATM Inhibitor-3	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC₅₀ of 0.71 nM. ATM Inhibitor-3 shows inhibition of *PI3K* kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .

HY-143276

(S,S,R)-AHPC-C6-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,S,R)-AHPC-C6-NH2 is a E3 Ligase Ligand-Linker Conjugate of HL-8 (HY-143275). HL-8 is a PROTAC molecule targeting PI3K kinase .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and *PI3K, with IC₅₀* values of 47, 663 and 5131 nM, respectively .

HY-164384

DFX117	PI3K Akt mTOR Apoptosis	Cancer
DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits *PI3K/Akt/mTOR* pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC₅₀s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .

HY-101798

MDVN1003	PI3K	Cancer
MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research .

HY-N5072

Desmethylglycitein 1 Publications Verification 4',6,7-Trihydroxyisoflavone	CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to *PI3K* in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-157706

PI(3,4)P2 (18:1) (ammonium salt)	PI3K	Cardiovascular Disease Metabolic Disease Cancer
PI(3,4)P2 (18:1) ammonium salt is a phosphatidylinositol 3 kinase (PI3K) activator. PI(3,4)P2 (18:1) ammonium salt is a polyphosphorylated phosphatidylinositol that promotes the activation of AKT (protein kinase B) by activating *PI3K*, which affects cell metabolism, growth and survival. PI(3,4)P2 (18:1) ammonium salt is also involved in regulating dynamic changes in the cytoskeleton, affecting cell morphology and movement. PI(3,4)P2 (18:1) ammonium salt can be used in research on the development of cancer, diabetes and cardiovascular disease .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

2,989 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 2,989 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L015

PI3K/Akt/mTOR Compound Library

652 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 652 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-165099

C-8 Ceramide-1-phosphate

Drug Delivery

C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .

Cat. No.	Product Name	Target	Research Area

HY-W005308

N-BOC-DL-serine methyl ester	Amino Acid Derivatives	Cancer
N-BOC-DL-serine methyl ester is a Serine derivative. N-BOC-DL-serine methyl ester is used for the synthesis of α,β-dehydro-α-amino acid. N-BOC-DL-serine methyl ester is also used for the synthesis of anti-cancer agent, such as quinazolinone derivative that inhibits PI3K activity, and tricyclic pyrolopyranopyridines that inhibits protein kinase activity .

Species:	Human (6)
Tag:	His (5) GST (5)
Source:	Sf9 insect cells (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P701752

	PK3C3 Protein, Human (Sf9, His, GST) PIK3C3; Phosphatidylinositol 3-kinase catalytic subunit type 3; PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34	Human	Sf9 insect cells
	The PI3KC3 protein is the catalytic subunit of the PI3K complex and mediates the formation of phosphatidylinositol 3-phosphate. PI3KC3-C1 initiates autophagosomes, whereas PI3KC3-C2 promotes autophagosome maturation and endocytosis. PK3C3 Protein, Human (Sf9, His, GST) is the recombinant human-derived PK3C3 protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of PK3C3 Protein, Human (Sf9, His, GST) is 886 a.a., .

HY-P701744

	PIK3R3 Protein, Human (Sf9, His, GST) PIK3R3; Phosphatidylinositol 3-kinase regulatory subunit gamma; PI3-kinase regulatory subunit gamma; PI3K regulatory subunit gamma; PtdIns-3-kinase regulatory subunit gamma; Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; PI3-kinase subunit p55-gamma; PtdIns-3-kinase regulatory subunit p55-gamma; p55PIK	Human	Sf9 insect cells
	PIK3R3 protein, through its SH2 domain, interacts with phosphorylated protein-tyrosine kinases, crucially regulating their kinase activity. During insulin stimulation, PIK3R3 binds to IRS-1. Operating as a heterodimer with a p110 catalytic subunit, it interacts with AXL, expanding its functional network. PIK3R3 Protein, Human (Sf9, His, GST) is the recombinant human-derived PIK3R3 protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of PIK3R3 Protein, Human (Sf9, His, GST) is 460 a.a., .

HY-P702976

	PIK3R2 Protein, Human (sf9, His) PI3K (p85 beta); Phosphatidylinositol 3-kinase regulatory subunit beta; PI3-kinase regulatory subunit beta; PI3K regulatory subunit beta; PtdIns-3-kinase regulatory subunit beta; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta (PI3-kinase subunit p85-beta; PtdIns-3-kinase regulatory subunit p85-beta)	Human	Sf9 insect cells
	PIK3R2 Protein, Human (sf9, His) is the recombinant human-derived PIK3R2, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P703176

	PIK3C2B Protein, Human (Sf9, GST) Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta; C2-PI3K; Phosphoinositide 3-kinase-C2-beta; PIK3C2B; Homo saPIens; Human; PI3K-C2-beta; kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3C2B Protein, Human (Sf9, GST) is the recombinant human-derived PIK3C2B, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P703177

	PIK3C2G Protein, Human (Sf9, His, GST) Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma; Phosphoinositide 3-kinase-C2-gamma; PIK3C2G; Homo saPIens; Human; PI3K-C2-gamma; kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3C2G Protein, Human (Sf9, His, GST) is the recombinant human-derived PIK3C2G, expressed by Sf9 insect cells , with His, GST labeled tag. ,

HY-P703582

	PIK3CG Protein, Human (Sf9, His, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PtdIns-3-kinase subunit p110-gamma; p110gamma; Phosphoinositide-3-kinase catalytic gamma polypeptide; Serine/threonine protein kinase PIK3CG; 2.7.11.1; p120-PI3K; PIK3CG; Homo saPIens; Human; PI3-kinase subunit gamma; kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CG Protein, Human (Sf9, His, GST) is the recombinant human-derived PIK3CG, expressed by Sf9 insect cells , with His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80866

	PI3 Kinase p55 gamma Antibody GRB1; P85A; PI3-kinase p85-alpha subunit; PI3K; PI3K p85-alpha; P55G; PI3-kinase p85-gamma subunit; PI3K p85-gamma	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p55 gamma Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 54 kDa, targeting to PI3 Kinase p55 gamma. It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80865

	PI3 Kinase p110 gamma Antibody (YA690) 1 Publications Verification PI3K; PIK3; PI3CG; PI3Kgamma; p110gamma; p120-PI3K	WB	Human
	PI3 Kinase p110 gamma Antibody (YA690) is a non-conjugated and Mouse origined monoclonal antibody about 126 kDa, targeting to PI3 Kinase p110 gamma (2D10). It can be used for WB assays with tag free, in the background of Human.

HY-P80867

	PI3 Kinase p85 alpha Antibody (YA689) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-P	Human, Mouse, Rat
	PI3 Kinase p85 alpha Antibody (YA689) is a non-conjugated and Mouse origined monoclonal antibody about 84 kDa, targeting to PI3 Kinase p85 alpha (1C8). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80846

	Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody 1 Publications Verification PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat, Monkey
	Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 84 kDa, targeting to Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199). It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P83044

	PIK3C3 Antibody (YA2789) Phosphatidylinositol 3-kinase catalytic subunit type 3 (EC:2.7.1.137); PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34; VPS34 antibodyPIK3C3；	WB, IHC-P	Human, Mouse, Rat
	PIK3C3 Antibody (YA2789) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2789), targeting PIK3C3, with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). PIK3C3 Antibody (YA2789) can be used for WB, IHC-P experiment in human, mouse, rat background.

HY-P81211

	phospho-PI3 Kinase p110 beta (Ser1070) Antibody 1 Publications Verification PI3-kinase p110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; PIk3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	phospho-PI3 Kinase p110 beta (Ser1070) Antibody is an unconjugated, approximately 110-123 kDa, rabbit-derived, anti-phospho-PI3 Kinase p110 beta (Ser1070) polyclonal antibody. phospho-PI3 Kinase p110 beta (Ser1070) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, guinea pig background without labeling.

HY-P81162

	PI3 Kinase p110 alpha/PIK3CA Antibody PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PIK3CA Antibody is an unconjugated, approximately 110 kDa, rabbit-derived, anti-PIK3CA monoclonal antibody. PIK3CA Antibody can be used for: WB, ICC/IF, IP expriments in human, mouse, rat background without labeling.

HY-P81872

	PI3 Kinase p110 delta Antibody (YA1617) PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1617), targeting PI3 Kinase p110 delta, with a predicted molecular weight of 119 kDa (observed band size: 119 kDa). PI3 Kinase p110 delta Antibody (YA1617) can be used for WB, ICC/IF experiment in human, mouse, rat background.